Molecular subtyping of brain metastasis-related genes in lung adenocarcinoma via scRNA-seq and bulk RNA-seq integration: A focus on TPX2.

IF 6.7 2区 医学 Q1 ONCOLOGY
Gang Xiao, Jiaoyang Ning, Su Wen, Liu Chen, Hao Wen, Keqin Zhang, Jie Yang, Qi Wu, Jing Zhang, Guilong Tanzhu, Min Su, Haibin Deng, Rongrong Zhou
{"title":"Molecular subtyping of brain metastasis-related genes in lung adenocarcinoma via scRNA-seq and bulk RNA-seq integration: A focus on TPX2.","authors":"Gang Xiao, Jiaoyang Ning, Su Wen, Liu Chen, Hao Wen, Keqin Zhang, Jie Yang, Qi Wu, Jing Zhang, Guilong Tanzhu, Min Su, Haibin Deng, Rongrong Zhou","doi":"10.21147/j.issn.1000-9604.2026.05.08","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Brain metastasis (BrM) is a common complication of advanced lung cancer with extremely poor prognosis. This study aimed to establish a molecular classification system for stratifying non-small cell lung cancer (NSCLC)-BrM patients and predicting survival, and to identify key BrM-related molecules and elucidate their mechanisms as potential therapeutic targets.</p><p><strong>Methods: </strong>We integrated single-cell and bulk transcriptomic data to construct molecular subtyping models for predicting lung cancer prognosis and immune microenvironment, and to screen key molecules driving BrM. Based on H1299 and PC9-BrM cells, <i>in vitro</i> experiments demonstrated the regulatory role and mechanism of targeting protein for Xklp2 (TPX2) in lung cancer BrM.</p><p><strong>Results: </strong>We identified 20 BrM-associated genes. Consensus clustering based on these genes stratified patients into two subtypes, with patients in Subtype 2 showing significantly worse overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS). Mechanistic analyses revealed marked activation of proliferation-related pathways in Subtype 2. TPX2 was identified as a critical mediator, with significantly elevated expression in BrM lesions compared with primary lung cancer lesions, and TPX2 overexpression correlated with poorer prognosis. Functional assays in H1299 and PC9-BrM cells demonstrated that <i>TPX2</i> knockdown markedly impaired proliferation, clonogenicity, migration, and invasion. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses and Western blotting validation further indicated that TPX2 likely promotes NSCLC-BrM by activating c-MYC and the epithelial-mesenchymal transition (EMT) process.</p><p><strong>Conclusions: </strong>Our study established a molecular classification system that effectively stratifies NSCLC-BrM patients and predicts survival. Moreover, TPX2 promotes NSCLC-BrM through c-MYC/EMT regulation, offering new insights for targeted therapeutic strategies.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 5","pages":"606-623"},"PeriodicalIF":6.7000,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746056/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21147/j.issn.1000-9604.2026.05.08","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Brain metastasis (BrM) is a common complication of advanced lung cancer with extremely poor prognosis. This study aimed to establish a molecular classification system for stratifying non-small cell lung cancer (NSCLC)-BrM patients and predicting survival, and to identify key BrM-related molecules and elucidate their mechanisms as potential therapeutic targets.

Methods: We integrated single-cell and bulk transcriptomic data to construct molecular subtyping models for predicting lung cancer prognosis and immune microenvironment, and to screen key molecules driving BrM. Based on H1299 and PC9-BrM cells, in vitro experiments demonstrated the regulatory role and mechanism of targeting protein for Xklp2 (TPX2) in lung cancer BrM.

Results: We identified 20 BrM-associated genes. Consensus clustering based on these genes stratified patients into two subtypes, with patients in Subtype 2 showing significantly worse overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS). Mechanistic analyses revealed marked activation of proliferation-related pathways in Subtype 2. TPX2 was identified as a critical mediator, with significantly elevated expression in BrM lesions compared with primary lung cancer lesions, and TPX2 overexpression correlated with poorer prognosis. Functional assays in H1299 and PC9-BrM cells demonstrated that TPX2 knockdown markedly impaired proliferation, clonogenicity, migration, and invasion. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses and Western blotting validation further indicated that TPX2 likely promotes NSCLC-BrM by activating c-MYC and the epithelial-mesenchymal transition (EMT) process.

Conclusions: Our study established a molecular classification system that effectively stratifies NSCLC-BrM patients and predicts survival. Moreover, TPX2 promotes NSCLC-BrM through c-MYC/EMT regulation, offering new insights for targeted therapeutic strategies.

通过scRNA-seq和大量RNA-seq整合对肺腺癌脑转移相关基因的分子分型:以TPX2为重点。
目的:脑转移(BrM)是晚期肺癌的常见并发症,预后极差。本研究旨在建立非小细胞肺癌(non-small cell lung cancer, NSCLC)-BrM患者分层和生存预测的分子分类体系,识别brm相关的关键分子,并阐明其作为潜在治疗靶点的机制。方法:整合单细胞和大量转录组学数据,构建预测肺癌预后和免疫微环境的分子分型模型,筛选驱动BrM的关键分子。基于H1299和PC9-BrM细胞,体外实验验证了Xklp2 (TPX2)靶蛋白在肺癌BrM中的调控作用及机制。结果:共鉴定出20个brm相关基因。基于这些基因的共识聚类将患者分为两种亚型,亚型2患者的总生存期(OS)、无进展生存期(PFS)和疾病特异性生存期(DSS)明显较差。机制分析显示亚型2中增殖相关通路的显著激活。TPX2被认为是一个关键的调节因子,与原发性肺癌病变相比,TPX2在BrM病变中的表达显著升高,TPX2过表达与预后较差相关。对H1299和PC9-BrM细胞的功能分析表明,TPX2基因敲低可显著抑制细胞增殖、克隆原性、迁移和侵袭。基因本体(GO)和京都基因与基因组百科全书(KEGG)分析以及Western blotting验证进一步表明,TPX2可能通过激活c-MYC和上皮-间质转化(EMT)过程来促进NSCLC-BrM。结论:我们的研究建立了一个分子分类系统,可以有效地对NSCLC-BrM患者进行分层并预测生存率。此外,TPX2通过调节c-MYC/EMT促进NSCLC-BrM,为靶向治疗策略提供了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
9.80%
发文量
1726
审稿时长
4.5 months
期刊介绍: Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631) is published by AME Publishing Company in association with Chinese Anti-Cancer Association.It was launched in March 1995 as a quarterly publication and is now published bi-monthly since February 2013. CJCR is published bi-monthly in English, and is an international journal devoted to the life sciences and medical sciences. It publishes peer-reviewed original articles of basic investigations and clinical observations, reviews and brief communications providing a forum for the recent experimental and clinical advances in cancer research. This journal is indexed in Science Citation Index Expanded (SCIE), PubMed/PubMed Central (PMC), Scopus, SciSearch, Chemistry Abstracts (CA), the Excerpta Medica/EMBASE, Chinainfo, CNKI, CSCI, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书